Company Overview and News

 
SPA / Sparton Corp. FORM 8-K (Current Report)

2018-04-16 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
Upvote Downvote

 
Sparton to Supply BAE with More Than $13 M in Ruggedized Displays

2018-03-27 asdnews
Sparton Corporation (NYSE:SPA) under the brand Aydin Displays, a leader in the ruggedized displays, computers, and peripherals market has been awarded a contract worth over $13 million to supply BAE Systems with ruggedized Flat Panel Displays for a program supporting the Navy. Aydin Displays is contracted to deliver more than 600 displays over a two and a half year period.
Upvote Downvote

 
SPA / Sparton Corp. / GAMCO INVESTORS, INC. ET AL - null (Activist Investment)

2018-03-09 sec.gov
  SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
SPA / Sparton Corp. / GAMCO INVESTORS, INC. ET AL - null (Activist Investment)

2018-03-09 sec.gov
  SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
Sparton and Ultra Electronics USSI JV (ERAPSCO) Awarded $28.4m for US Navy Sonobuoy Contracts

2018-03-07 asdnews
Sparton Corporation (NYSE:SPA) and Ultra Electronics Holdings plc (ULE) announce the award of subcontracts valued at $28.4 million to their ERAPSCO joint venture, for the manufacture of sonobuoys for the United States Navy. The award is a GFY18 ERAPSCO Indefinite Delivery Indefinite Quantity (IDIQ) contract release for sonobuoy requirements under ERAPSCO’s five year contract. ERAPSCO will provide production subcontracts in the amount of $17.
Upvote Downvote

 
Ultra takeover of Sparton collapses

2018-03-05 janes
Negotiations behind the planned acquisition of Sparton Corporation by Ultra Electronics have been terminated, Ultra Electronics announced on 5 March.
Upvote Downvote

 
SPA / Sparton Corp. FORM 8-K (Current Report)

2018-03-05 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
Upvote Downvote

1
Deals of the day-Mergers and acquisitions

2018-03-05 reuters
March 5 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1100 GMT on Monday:
Upvote Downvote

 
UPDATE 1-Britain's Ultra Electronics ends Sparton deal, shares slump

2018-03-05 reuters
(Reuters) - Ultra Electronics said on Monday it terminated the $234 million acquisition of Sparton Corp due to anti-trust concerns raised by the U.S. Department of Justice, sending the British defense contractor shares down 17 percent.
Upvote Downvote

 
UPDATE 1-UK Stocks-Factors to watch on March 5

2018-03-05 reuters
* Tesco-Booker: Tesco, Britain’s biggest retailer, has completed the 4 billion pound ($5.51 billion) takeover of Booker, the country’s largest wholesaler, the companies said on Monday.
Upvote Downvote

 
Britain's Ultra Electronics terminates $234 mln Sparton deal

2018-03-05 reuters
March 5 (Reuters) - British defence contractor Ultra Electronics said it terminated the $234 million acquisition of Sparton Corp following an unfavourable anti-trust review outcome from the U.S. Department of Justice.
Upvote Downvote

 
SPA / Sparton Corp. / Tappan Street Partners LLC - AMENDED FORM SC 13G (Passive Investment)

2018-02-16 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G (Amendment No. 2)   Under the Securities Exchange Act of 1934*   Sparton Corporation (Name of Issuer)   Common Stock par value $1.25 per share   (Title of Class of Securities)   847235108   (CUSIP Number)   December 31, 2017   (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:     ☐ Rule 13d-1(b)         ☒ Rule
Upvote Downvote

 
SPA / Sparton Corp. / Tappan Street Partners LLC - AMENDED FORM SC 13G (Passive Investment)

2018-02-16 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G (Amendment No. 2)   Under the Securities Exchange Act of 1934*   Sparton Corporation (Name of Issuer)   Common Stock par value $1.25 per share   (Title of Class of Securities)   847235108   (CUSIP Number)   December 31, 2017   (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:     ☐ Rule 13d-1(b)         ☒ Rule
Upvote Downvote

 
SPA / Sparton Corp. / VANGUARD GROUP INC - 3G (Passive Investment)

2018-02-09 sec.gov
spartoncorp.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 0 )*       Name of issuer:  Sparton Corp     Title of Class of Securities:  Common Stock     CUSIP Number:  847235108     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (X) Rule 13d-1(b)
Upvote Downvote

 
SPA / Sparton Corp. / VANGUARD GROUP INC - 3G (Passive Investment)

2018-02-09 sec.gov
spartoncorp.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 0 )*       Name of issuer:  Sparton Corp     Title of Class of Securities:  Common Stock     CUSIP Number:  847235108     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (X) Rule 13d-1(b)
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 847235108